Phaseline

Targets › ALPP

ALPP (Alkaline phosphatase, placental type): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.

Alkaline phosphatase that can hydrolyze various phosphate compounds. (UniProt, P05187)

Open in Phaseline: the race on ALPP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai EpimAb BiotherapeuticsEMB-15
Bi-specific antibody against ALPP/ALPG and CD3; T-cell engager
ALPP, ALPG, CD3Phase 1Locally Advanced or Metastatic Solid TumorsMay 2029

Conditions

Locally Advanced or Metastatic Solid Tumors (1)

Modalities

protein or peptide (1)

Companies

Shanghai EpimAb Biotherapeutics (1)

Related targets

ALPG (1) CD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.